Lupron Depot (Leuprolide Acetate) Patent Expiration, LOE Window & CMS Spending

Lupron Depot (Leuprolide Acetate) by AbbVie: FDA Orange Book LOE 2031-02-05, 0 AB generics, $246.3M 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAbbVie
FDA Application & PathwayN019732 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2031-02-05
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$246.3M
2024 Medicare Part D Spend$164.0M
2024 Medicaid Spend$82.3M
Reported Wholesale Price Change (CA SB 17)6 WAC filings (max 17.0% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AbbVie across sibling Meru public-data platforms.